A number of different regimens have evolved for the mobilisation of peripheral blood stem cells for autologous transplantation in patients with lymphoma or myeloma. A successful regimen could be defined as one which consistently resulted in the collection of an optimal number of CD34
The use of autologous peripheral blood stem cell (PBSC) rescue is increasingly being used instead of bone marrow for the support of patients undergoing high-dose therapy for haematological malignancies. 1 The primary reason for the switch to PBSC is the more rapid haematological reconstitution seen with PBSC compared to bone marrow. 2 A number of studies have clearly demonstrated that for the beneficial effects of PBSC on engraftment to be realised sufficient numbers of progenitor cells are required to be infused following high-dose therapy. For most purposes enumeration of the number of CD34 ϩ cells in PBSC harvests has been regarded as a reliable index of engraftment potential. In this context most groups have aimed at a CD34 ϩ cell dose of between 2.0 and 5.0 × 10 6 /kg as being optimal for rapid engraftment, [3] [4] [5] [6] although there is evidence that higher doses of CD34 ϩ cells (Ͼ15 × 10 6 /kg) may accelerate haemopoietic recovery further. 7, 8 However, autologous PBSC transplantation can be performed with a lower (sub-optimal) number of CD34 ϩ cells, but under these circumstances neutrophil and particularly platelet recovery is delayed [4] [5] [6] [7] [8] [9] and a threshold value of 1.0 × 10 6 /kg CD34 ϩ cells has been identified as the minimum number of cells required. 9, 10 The major clinical indications for high-dose therapy and PBSC transplantation in Europe are the lymphoproliferative diseases including Hodgkin's disease, non-Hodgkin's lymphoma and myeloma. 1 A number of regimens for mobilisation of PBSC from these patients have been reported including G-CSF alone or, more frequently, variable doses of cyclophosphamide in combination with G-CSF or GM-CSF. In general there is evidence that more CD34 ϩ cells can be collected following the administration of chemotherapy and a growth factor than after a growth factor alone. 5, 11 More recently, a number of investigators have reported on the efficacy of combination chemotherapy regimens for PBSC mobilisation particularly in lymphoma [12] [13] [14] [15] [16] which appear to be superior to cyclophosphamide and growth factor. The purpose of this article is to review the current status of PBSC mobilisation in lymphoproliferative diseases in the light of these observations with the proviso that any conclusions must be circumspect given the general lack of randomised trials in this area and the difficulties inherent in comparing results from different studies.
Lymphoma

PBSC mobilisation with cyclophosphamide and growth factors
Over the last decade the use of a specific mobilisation step with cyclophosphamide and a growth factor has been the gold-standard for PBSC collection. However, the dose of cyclophosphamide used, growth factor type, dose and scheduling have been variable (see Table 1 ). Broadly, the doses of cyclophosphamide needed can be categorised as high dose (6) (7) ). The use of cyclophosphamide relates to the original reports of its efficacy as a single agent, without growth factor for PBSC mobilisation, 17, 18 where it was found that high-dose cyclophosphamide (7 g/m ). 18 Likewise, in a sequential, non-randomised study of cyclophosphamide (7 20 reported that a second mobilisation procedure with 7 g/m 2 cyclophosphamide resulted in an augmented CFU-GM yield in the apheresis product. The efficacy of mobilisation may also be augmented by the addition of etoposide and in a study of patients with relapsed or refractory Hodgkin's disease 28 out of 38 patients (74%) achieved greater than the target dose of 2.5 × 10 6 CD34 ϩ cells/kg using the combination of cyclophosphamide (4 g/m 2 ) plus etoposide. 21 Although from these studies high-dose cyclophosphamide appears to be more effective at PBSC mobilisation than intermediate or low doses, its use has been associated with a longer duration of cytopenia and a high rate of nonhaematological morbidity including haemorrhagic cystitis. 18, 22 These risks have led many groups to explore the use of lower doses of cyclophosphamide (Ͻ4 g/m 2 ) with the aim of reducing the procedural morbidity. Cyclophosphamide at doses of 1.5 g/m 2 to 3 g/m 2 have now been reported with low toxicity and minimal requirements for hospitalisation. 6, 10, 23 Using cyclophosphamide 1.5 g/m 2 combined with G-CSF, Watts et al 10 reported that 87% of lymphoma patients achieved an 'adequate' harvest which was defined as containing Ͼ1 × 10 6 /kg CD34 ϩ cells, however only 50% achieved an 'optimal' harvest (ie associated with rapid engraftment) of Ͼ3.5 × 10 6 /kg CD34 ϩ cells. Cyclophosphamide at this dosage schedule was well tolerated and only 5% of patients required hospitalisation. 10 Using a higher dose of cyclophosphamide (3 g/m 2 ) we obtained an optimal CD34
ϩ cell dose, defined as Ͼ2.5 × 10 6 /kg, in 30 out of 50 (60%) lymphoma patients 13 and in 47 out of 64 (73%) of patients with myeloma which rose to 90% in patients who had only received initial pre-mobilisation chemotherapy with infusional vincristine, adriamycin and dexamethasone (VAD) or methylprednisolone (VAMP). 24 In breast cancer patients low-dose cyclophosphamide (2 g/m 2 ) plus etoposide has proved as effective a mobilisation regimen as cyclophosphamide 4 g/m 2 and was associated with significantly less toxicity. 25 To a certain extent it is difficult to compare the success rate of these differing mobilisation regimens using cyclophosphamide due to the different case mix. In this context it is well recognised that previous chemotherapy and radiotherapy can adversely influence the yield of CD34 ϩ cells. [9] [10] [11] 26 Also, there is evidence that patients with lowgrade lymphoma are more likely to be poor mobilisers, 27 such that the number of these cases in any series is likely to affect the overall results. It is possible, however, to make some general conclusions. Firstly, it is clear that low-dose to intermediate-dose cyclophosphamide and G-CSF can successfully mobilise PBSC from the majority of patients with lymphoproliferative disorders with minimal toxicity. 6, 10, 23 This may be further enhanced by the addition of etoposide. 21 However, a significant proportion, amounting to perhaps 40% of patients, particularly those who have received multiple cycles of previous chemotherapy or radiotherapy will fail to mobilise an optimal number of CD34 ϩ cells although many will still have sufficient CD34
ϩ cells collected to progress to high-dose therapy. Finally, mobilisation with cyclophosphamide has the disadvantage of requiring a specific mobilisation step rather than being an integral part of therapy as is the case with the second-generation combination chemotherapy mobilisation regimens that have now been reported.
PBSC mobilisation using salvage combination chemotherapy regimens
A number of combination chemotherapy regimens have been used for PBSC mobilisation particularly in lymphoma patients, some of which have been reported to be more effective than cyclophosphamide plus growth factors (Table  1) . These regimens also have the significant advantage of being integrated into patient treatment and provide a dual function of mobilisation and salvage anti-lymphoma therapy. Pettengell et al 28, 29 reported that the VAPEC-B regimen combined with G-CSF was effective in PBSC mobilisation, both in non-Hodgkin's lymphoma and relapsed Hodgkin's disease, although the number of CD34 ϩ cells collected was lower in the pre-treated Hodgkin's disease patients (median 4.65 × 10 6 /kg, range 1.9-28) compared to the NHL patients who were mobilised early in their disease (median 11.6 × 10 6 /kg, range 4.3-398). 29 However, these numbers of cells were achieved following a single 14 l apheresis and the chemotherapy regimen was administered on an outpatient basis. For patients with relapsed lymphoma, either Hodgkin's disease or non-Hodgkin's lymphoma, the Dexa-BEAM regimen has been described as an effective treatment protocol and has also been utilised for mobilising PBSC. Dreger et al 12 initially reported on 15 patients with refractory lymphoma who received G-CSF (5 g/kg/day) from day 8 of Dexa-BEAM and collected a median of 5.7 × 10 6 /kg CD34 ϩ cells from two to six leucapheresis procedures. However, inadequate collection of PBSC with Dexa-BEAM has been seen in some heavily pre-treated patients. 26, 30 Furthermore, Dexa-BEAM is strongly myelosuppressive with the median time to the initiation of PBSC collection being 18 days and most patients requiring 2-3 weeks of hospitalisation with a high risk of neutropenic fever. 26, 30 Our group has recently reported on the use of the IVE regimen (ifosfamide, epirubicin and etoposide) combined with G-CSF for combined salvage therapy and PBSC mobilisation in lymphoma patients, 13 /kg with cyclophosphamide (P Ͻ 0.0001). The superiority of IVE mobilisation was clearly demonstrated in that in all four patients who had failed with cyclophosphamide and G-CSF were successfully mobilised with IVE. 13 In a re-analysis of this experience in a series of 45 lymphoma patients, we obtained an optimal harvest (Ͼ2. /kg in 94% of patients. When they compared these results with a comparable group of patients with Hodgkin's disease treated with Dexa-BEAM plus G-CSF they found the MIME regimen to be a more efficient mobilising regimen which had less toxicity. 14 In another study Martinez et al 15 used IAPVP (ifosfamide, etoposide, AraC and methyl prednisolone) combined with G-CSF as a mobilising regimen in patients with advanced lymphoma. They were able to collect more than their target of 3.5 × 10 6 /kg CD34 ϩ cells in all 15 patients and interestingly this regimen appeared equally effective when using a lower dose of G-CSF (50 g/m 2 ). 31 Watts et al 16 ) and G-CSF. Patients with low-grade NHL may represent a particular challenge for PBSC mobilisation. In particular, these patients may have been exposed to a variety of previous treatments which may adversely affect PBSC collections including multiple courses of oral alkylating agents, radiotherapy and fludarabine therapy. Haas et al 32 mobilised 48 such patients mobilised with the HAM regimen (high-dose AraC and mitoxantrone). They collected a median of 6.9 × 10 6 /kg CD34 ϩ cells/kg in a median of two leucaphereses with those patients mobilised in first remission, and those who had received less than six cycles of previous chemotherapy tended to have better results. In contrast, others have reported suboptimal PBSC harvest results in lowgrade NHL patients 27, 33 with approximately 25% of patients failing to mobilise Ͼ1 × 10 6 /kg CD34 ϩ cells, using lowdose cyclophosphamide plus G-CSF. 33 For heavily pretreated patients with low-grade NHL we have obtained significantly improved results with the IVE regimen collecting a median of 7.36 × 10 In conclusion, with the possible exception of Dexa-BEAM in this series of results, regimens designed for salvage therapy of lymphoma would all appear to indicate superiority of either intermediate-or low-dose cyclophosphamide and G-CSF. Although no randomised studies have been performed this interpretation is supported by the fact that some patients have been reported who have been successfully mobilised with salvage regimens who had previously failed with cyclophosphamide/G-CSF.
Myeloma
As for lymphoma, comparing the results of different PBSC mobilisation studies in myeloma is problematic due to the marked effect that prior radiotherapy and chemotherapy with alkylating agents and radiotherapy has on mobilisation in this disease. 34, 35 Thus, the patient characteristics will have a major impact on the success of PBSC mobilisation. This is exemplified by our results in a cohort of patients who had received prior treatment with VAD-based regimens only. In these patients we were able to collect a median of 3.25 × 10 ) and G-CSF. 6, 24 In several reported studies in myeloma high-dose cyclophosphamide in combination with growth factors has been used as a standard approach to PBSC mobilisation (summarised in Table 2 ). In an early study Boiron et al 36 reported that the addition of GM-CSF to high-dose cyclophosphamide (7 g/m 2 ) enhanced the yield of CFU-GM collected. Demirer et al 35 /kg compared to 5.6 × 10 6 /kg), however, the target dose of Ͼ4 × 10 6 /kg CD34 ϩ cells required for a programme of tandem transplantation was achieved in a comparable number of patients and the engraftment kinetics following high-dose melphalan were comparable in the two groups. The authors concluded that for the majority of myeloma patients G-CSF alone was satisfactory for PBSC mobilisation and that the larger number of CD34 ϩ cells collected with high-dose cyclophosphamide was not necessary and resulted in significantly more toxicity. Furthermore, the cyclophosphamide itself had little specific anti-myeloma activity. The dose of G-CSF used is clearly important when used as a single agent. Higher doses of G-CSF (24 g/kg/day) have been reported to result in the improved effectiveness of PBSC collection in a study of predominantly lymphoma patients when compared to conventional doses (10 g/kg/day), 39 and high-dose G-CSF (24 g/kg/day) was found to give rise to comparable yields of PBSC as were obtained in lymphoma patients following mobilisation with Dexa-BEAM and G-CSF. 30 Also Knudsen 40 found that lower doses of G-CSF (10 g/kg/day) were not as effective a regimen as cyclophosphamide (4 g/m 2 ) and G-CSF. These results suggest that the optimal dose of G-CSF alone for mobilisation is 16-24 g/kg/day.
These studies help clarify the situation concerning the optimal mobilisation regimens for myeloma patients (see Table 2 ). Although a highly effective mobilisation regimen, high-dose cyclophosphamide has significant toxicity. The alternatives are a lower dose of cyclophosphamide and growth factor combination or G-CSF alone. In our experience cyclophosphamide at 3 g/m 2 is well tolerated and is highly effective as a mobilisation regimen for early stage myeloma patients who have only received prior therapy with VAD or VAD-based regimens and remains our choice for PBSC mobilisation. Furthermore, it is possible to collect sufficient CD34 ϩ cells to undertake CD34 ϩ selection. G-CSF alone even when used at doses of 16 g/kg is not as effective a mobilising regimen as high-dose cyclophosphamide 39 and although there have been no direct comparisons it is probably not as effective as low-dose cyclophosphamide either. However, as pointed out, G-CSF alone is easy to schedule, is more predictable than chemotherapy plus growth factor combinations and toxicity is minimised. 30, 38, 39 
Conclusions
Clearly further studies, particularly randomised ones, are required to clarify some of the issues raised in this review. There is little information concerning the optimal dosage of growth factors when used in combination with chemotherapy. In particular, does high-dose G-CSF (16-24 g/kg/day) when combined with salvage chemotherapy improve results in poor mobilisers? However, as regards the current status of PBSC mobilisation we could make some tentative conclusions. Firstly, in relapsed lymphoma the use of a combined salvage mobilisation schedule is an attractive option and is almost certainly more effective than low-or intermediate-dose cyclophosphamide. There is also the advantage of avoiding delay in lymphoma-specific therapy that is unavoidable if a specific mobilisation step with cyclophosphamide is used. A number of salvage regimens have been described and to a certain extent the final choice will depend upon local preferences. In myeloma the choice of mobilisation regimen is perhaps less clear. For heavily pre-treated patients, particularly those who have received prior alkylating agent therapy, the use of low-or intermediate-dose cyclophosphamide and growth factors rather than G-CSF alone would appear to be optimal. For patients receiving prior treatment with VAD or similar regimens which are relatively non-myelotoxic, high-dose G-CSF alone would be an alternative mobilisation schedule. If procedures such as CD34 ϩ cell selection are planned then the use of cyclophosphamide-based regimens will result in a higher start number and percentage of CD34 ϩ cells thereby maximising CD34
ϩ cell yields 41 and is therefore the probable regimen of choice.
The place of new cytokines such as human megakaryocyte growth and development factor (MGDF) and stem cell factor (SCF) in combination with G-CSF or indeed in combination with chemotherapy and G-CSF remains to be evaluated. It will be of particular interest if these agents are demonstrated to be of value in the small minority of patients who fail current mobilisation strategies.
